Literature DB >> 1828838

Frequency of the Tay-Sachs disease splice and insertion mutations in the UK Ashkenazi Jewish population.

E C Landels1, I H Ellis, A H Fensom, P M Green, M Bobrow.   

Abstract

Tay-Sachs disease is a lethal neurodegenerative disorder caused by deficiency of the lysosomal enzyme beta-hexosaminidase A and inherited in an autosomal recessive fashion; carriers of the disease are 10 times more frequent in the Ashkenazi Jewish community than in the general population. Over 90% of North American Ashkenazi carriers tested have been shown to have either a splice site mutation at the boundary of exon 12 and intron 12 in the beta-hexosaminidase alpha subunit gene, or a 4 base pair insertion in exon 11. We describe simple assays involving amplification of DNA across these two mutation sites by polymerase chain reaction and the results of screening 75 subjects are given. The frequencies of the splice and insert mutations in 41 UK Ashkenazi carriers (20% to 80%, respectively) were similar to those found in the North American community. Twelve Ashkenazi subjects classified as non-carriers on enzyme assay were found to be negative for both mutations tested. All Ashkenazi carriers tested (both obligate carriers and those picked up by population screening) had either the splice or insert mutations; in contrast to this, only 21% of the non-Ashkenazi carriers had one or other of these mutations. It is concluded that within the carrier screening programmes for the Ashkenazi community, assays for the splice and insert mutations, together with an assay recently described for a mutation causing the rarer adult onset form of the disease, will prove useful as confirmatory tests for subjects who give positive or borderline results when screened on enzyme assay.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828838      PMCID: PMC1016801          DOI: 10.1136/jmg.28.3.177

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  13 in total

Review 1.  Natural history and inherited disorders of a lysosomal enzyme, beta-hexosaminidase.

Authors:  E F Neufeld
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

2.  Tay-Sachs disease heterozygote detection: use of a centrifugal analyser for automation of hexosaminidase assays with two different artificial substrates.

Authors:  E C Landels; I H Ellis; M Bobrow; A H Fensom
Journal:  J Med Genet       Date:  1991-02       Impact factor: 6.318

3.  Identification of an altered splice site in Ashkenazi Tay-Sachs disease.

Authors:  E Arpaia; A Dumbrille-Ross; T Maler; K Neote; M Tropak; C Troxel; J L Stirling; J S Pitts; B Bapat; A M Lamhonwah
Journal:  Nature       Date:  1988-05-05       Impact factor: 49.962

4.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

5.  Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group.

Authors:  R Myerowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

6.  Human beta-hexosaminidase alpha chain: coding sequence and homology with the beta chain.

Authors:  R Myerowitz; R Piekarz; E F Neufeld; T B Shows; K Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

7.  Organization of the gene encoding the human beta-hexosaminidase alpha-chain.

Authors:  R L Proia; E Soravia
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

8.  Molecular basis of adult-onset and chronic GM2 gangliosidoses in patients of Ashkenazi Jewish origin: substitution of serine for glycine at position 269 of the alpha-subunit of beta-hexosaminidase.

Authors:  B H Paw; M M Kaback; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult form of Tay-Sachs disease.

Authors:  R Navon; R L Proia
Journal:  Science       Date:  1989-03-17       Impact factor: 47.728

10.  Estimation of the frequency of hexosaminidase a variant alleles in the American Jewish population.

Authors:  D A Greenberg; M M Kaback
Journal:  Am J Hum Genet       Date:  1982-05       Impact factor: 11.025

View more
  7 in total

1.  Novel mutations and DNA-based screening in non-Jewish carriers of Tay-Sachs disease.

Authors:  B R Akerman; M R Natowicz; M M Kaback; M Loyer; E Campeau; R A Gravel
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

2.  Heterozygosity for Tay-Sachs disease in non-Jewish Americans with ancestry from Ireland or Great Britain.

Authors:  M van Bael; M R Natowicz; J Tomczak; E E Grebner; E M Prence
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

3.  Beta-hexosaminidase splice site mutation has a high frequency among non-Jewish Tay-Sachs disease carriers from the British Isles.

Authors:  E C Landels; P M Green; I H Ellis; A H Fensom; M Bobrow
Journal:  J Med Genet       Date:  1992-08       Impact factor: 6.318

4.  A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening.

Authors:  B L Triggs-Raine; E H Mules; M M Kaback; J S Lim-Steele; C E Dowling; B R Akerman; M R Natowicz; E E Grebner; R Navon; J P Welch
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

5.  Mutational analyses of Tay-Sachs disease: studies on Tay-Sachs carriers of French Canadian background living in New England.

Authors:  B Triggs-Raine; M Richard; N Wasel; E M Prence; M R Natowicz
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

6.  A second mutation associated with apparent beta-hexosaminidase A pseudodeficiency: identification and frequency estimation.

Authors:  Z Cao; M R Natowicz; M M Kaback; J S Lim-Steele; E M Prence; D Brown; T Chabot; B L Triggs-Raine
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

Review 7.  A Prospective Treatment Option for Lysosomal Storage Diseases: CRISPR/Cas9 Gene Editing Technology for Mutation Correction in Induced Pluripotent Stem Cells.

Authors:  Chloe L Christensen; Francis Y M Choy
Journal:  Diseases       Date:  2017-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.